p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system

Cell Biology International

Volumn 23, Issue 5, 1999, Pages 323-334

  Sablina, Anna A ^a   Agapova, Larissa S ^a   Chumakov, Peter M ^b   Kopnin, Boris P ^a  

^a RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Cell cycle checkpoints; Microtubules; p53

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DEMECOLCINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53;

ANAPHASE; ANEUPLOIDY; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CLONE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME NUMBER; CONTROLLED STUDY; CYTOSKELETON; DEPOLYMERIZATION; DRUG ACCUMULATION; FIBROBLAST; GENETIC TRANSDUCTION; METAPHASE; MICROTUBULE; MICROTUBULE ASSEMBLY; NONHUMAN; POLYPLOIDY; RAT; SIGNAL TRANSDUCTION; SPINDLE CELL;

ANIMALIA; MURINAE; RODENTIA;

EID: 0032696428     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbir.1999.0362     Document Type: Article

References (61)

1. Agapova LS, Ilyinskaya GV, Turovets NA, Ivanov AV, Chumakov PM, Kopnin BP. Chromosome changes caused by alterations of p53 expression. Mutat Res. 354:1996;129-138.
2. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 92:1995;8493-8497.
3. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 55:1995;4623-4626.
4. Cahill DP, Lengauer C, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:1998;300-303.
5. Chernov MV, Stark GR. The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene. 14:1997;2503-2510.
6. Chernova OB, Chernov MV, Agarwal ML, Taylor WR, Stark GR. The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends Biochem Sci. 20:1995;431-434.
7. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 17:1995;501-508.
8. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
9. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57:1997;1013-1019.
10. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
11. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
12. El Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
13. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
14. Gualberto A, Kenneth A, Kozariewicz K, Tlsty TD. An oncogenic form p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A. 95:1998;5166-5171.
15. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 266:1994;1821-1828.
16. Harvey DM, Levine AJ. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5:1991;2375-2385.
17. Horikoshi N, Usheva A, Chen J, Levine AJ, Weinmann R, Shenk T. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol. 15:1995;227-234.
18. Hu MC, Qiu WR, Wang YP. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene. 15:1997;2277-2287.
19. Ishizaka Y, Chernov MV, Burns CM, Stark GR. p53-dependent growth arrest of REF52 cells containing newly amplified DNA. Proc Natl Acad Sci U S A. 92:1995;3224-3228.
20. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature. 381:1996;643-644.
21. Jamal S, Ziff EB. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene. 10:1995;2095-2101.
22. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitotis. J Cell Sci. 102:1992;401-416.
23. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
24. Khan SH, Wahl GM. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58:1998;396-401.
25. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
26. Kolch W, Heidecker G, Lloyd P, Rapp UR. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 349:1991;426-438.
27. Kondratov RV, Kuznetsov NV, Pugacheva EN, Almazov VP, Prasolov VS, Kopnin BP, Chumakov PM. Functional heterogeneity of p53-responsive elements. Mol Biol (Mosk). 30:1996;613-620.
28. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 18:1998;1055-1064.
29. Lees Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol. 12:1992;5041-5049.
30. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
31. Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:1998;3008-3019.
32. Meek DW. Post-translational modification of p53. Semin Cancer Biol. 5:1994;203-210.
33. Meek DW, Campbell LE, Jardine LJ, Knippschil DU, McKendrick L, Milne DM. Multi-site phosphorylation of p53 by protein kinases inducible by p53 and DNA damage. Biochem Soc Trans. 25:1997;416-419.
34. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
35. Milne DM, Palmer RH, Campbell DG, Meek DW. Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene. 7:1992;1361-1369.
36. Milne DM, Campbell DG, Caudwell FB, Meek DW. Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J Biol Chem. 269:1994;9253-9260.
37. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem. 270:1995;5511-5518.
38. Minn A-J, Boise L-H, Thompson C-B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:1996;2621-2631.
39. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
40. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
41. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:1995;4442-4449.
42. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res. 6:1994;71-77.
43. Orr-Weaver TL, Weinberg RA. A checkpoint on the road to cancer. Nature. 392:1998;223-224.
44. Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM, Gudkov AV. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A. 93:1996;10,309-10,314.
45. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1555:1995;3032-3040.
46. Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene. 8:1993;1183-1193.
47. Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol. 127:1994;1301-1310.
48. Rieder CL, Cole RW, Khodjakov A, Sluder G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. J Cell Biol. 130:1995;941-948.
49. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol. 8:1996;773-780.
50. Sablina A, Ilyinskaya G, Rubtsova S, Agapova L, Chumakov P, Kopnin B. Activation of p53-mediated cell cycle checkpoint in response to micronuclei formation. J Cell Sci. 111:1998;977-984.
51. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
52. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ, Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 89:1992;12,028-12,032.
53. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
54. Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
55. Townsend KJ, Trusty JL, Traupman MA, Eastman A, Craig RW. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene. 17:1998;1223-1234.
56. Wallner J, Gisslinger H, Gisslinger B, Gsur A, Gotzl M, Zochbauer S, Pirker R. MDR1 gene expression in chronic lymphocytic leukemia. Leuk Lymphoma. 13:1994;333-338.
57. Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst. 74:1985;759-765.
58. Zaichuk TA, Kuznetsov NV, Osovskaia VS, Kopnin BP, Chumakov PM. Specific DNA-binding properties of oncoprotein p53 in human tumor cells. Dokl Akad Nauk. 330:1993;379-382.
59. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 8:1993;1529-1535.
60. Zhan Q, Lord KA, Alamo I Jr, Hollander MC, Carrier F, Ron D, Kohn KW, Hoffman B, Liebermann DA, Fornace AJJ. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol. 14:1994;2361-2371.
61. Zhang W, McClain C, Gau JP, Guo XY, Deisseroth AB. Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function. Cancer Res. 54:1994;4448-4453.